Mechanisms controlling virulence thresholds of mixed viral populations

Journal of Virology

Volumn 85, Issue 19, 2011, Pages 9778-9788

  Lancaster, Karen Z ^a   Pfeiffer, Julie K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; CD155 ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; INTERFERON; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MICROBIOLOGICAL PARAMETERS; MIXED VIRAL POPULATION; MOUSE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVERTANT; VIRAL PHENOMENA AND FUNCTIONS; VIRULENCE THRESHOLD; VIRUS ATTENUATION; VIRUS IMMUNITY; VIRUS INACTIVATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POLIOMYELITIS; POLIOVIRUS; RODENT DISEASES; VIRULENCE; VIRUS ATTACHMENT;

MUS; MUS MUSCULUS; POLIOVIRUS; RNA VIRUSES;

EID: 80053961883     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00355-11     Document Type: Article

References (68)

1. Abecasis, A. B., A. M. Vandamme, and P. Lemey. 2009. Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J. Virol. 83:12917-12924.
2. Anonymous. 2009. Update on vaccine-derived polioviruses-worldwide, January 2008-June 2009. MMWR Morb. Mortal. Wkly. Rep. 58:1002-1006.
3. Arita, M., et al. 2005. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J. Virol. 79:12650-12657.
4. Barton, E. S., J. L. Connolly, J. C. Forrest, J. D. Chappell, and T. S. Dermody. 2001. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening. J. Biol. Chem. 276:2200-2211.
5. Bouchard, M. J., D. H. Lam, and V. R. Racaniello. 1995. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69:4972-4978.
6. Cello, J., et al. 2008. Growth phenotypes and biosafety profiles in poliovirusreceptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. J. Med. Virol. 80:352-359.
7. Cherkasova, E. A., et al. 2005. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J. Virol. 79:1062-1070.
8. Chumakov, K. M., L. B. Powers, K. E. Noonan, I. B. Roninson, and I. S. Levenbook. 1991. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. U. S. A. 88:199-203.
9. Crowder, S., and K. Kirkegaard. 2005. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nat. Genet. 37: 701-709.
10. Cuervo, N. S., et al. 2001. Genomic features of intertypic recombinant Sabin poliovirus strains excreted by primary vaccinees. J. Virol. 75:5740-5751.
11. Daley, J. K., L. A. Gechman, J. Skipworth, and G. F. Rall. 2005. Poliovirus replication and spread in primary neuron cultures. Virology 340:10-20.
12. de la Torre, J. C., C. Giachetti, B. L. Semler, and J. J. Holland. 1992. High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus. Proc. Natl. Acad. Sci. U. S. A. 89:2531-2535.
13. de la Torre, J. C., and J. J. Holland. 1990. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J. Virol. 64:6278-6281.
14. Diamond, M. S., et al. 2000. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74:4957-4966.
15. Domingo, E., et al. 1985. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance-a review. Gene 40:1-8.
16. Drake, J. W., B. Charlesworth, D. Charlesworth, and J. F. Crow. 1998. Rates of spontaneous mutation. Genetics 148:1667-1686.
17. Drake, J. W., and J. J. Holland. 1999. Mutation rates among RNA viruses. Proc. Natl. Acad. Sci. U. S. A. 96:13910-13913.
18. Duarte, E., D. Clarke, A. Moya, E. Domingo, and J. Holland. 1992. Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proc. Natl. Acad. Sci. U. S. A. 89:6015-6019.
19. Duarte, E. A., et al. 1994. Subclonal components of consensus fitness in an RNA virus clone. J. Virol. 68:4295-4301.
20. Ebihara, H., et al. 2006. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2:e73.
21. Eigen, M. 1993. Viral quasispecies. Sci. Am. 269:42-49.
22. Evans, D. M., et al. 1985. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550.
23. Furione, M., et al. 1993. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196:199-208.
24. Georgescu, M. M., M. Tardy-Panit, S. Guillot, R. Crainic, and F. Delpeyroux. 1995. Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus. J. Virol. 69:5278-5286.
25. Glinsky, G. V. Genomic analysis of pandemic (H1N1) 2009 reveals association of increasing disease severity with emergence of novel hemagglutinin mutations. Cell Cycle 9:958-970.
26. Goffe, A., T. M. Pollock, and F. L. Shand. 1961. Vaccination of adults with a British oral poliomyelitis vaccine prepared from Sabin strains. Br. Med. J. 2:272-275.
27. Gromeier, M., and E. Wimmer. 1998. Mechanism of injury-provoked poliomyelitis. J. Virol. 72:5056-5060.
28. Guest, S., E. Pilipenko, K. Sharma, K. Chumakov, and R. P. Roos. 2004. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J. Virol. 78: 11097-11107.
29. Holland, J., et al. 1982. Rapid evolution of RNA genomes. Science 215: 1577-1585.
30. Ida-Hosonuma, M., et al. 2005. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J. Virol. 79:4460-4469.
31. Ji, H., et al. 2010. HIV drug resistance surveillance using pooled pyrosequencing. PLoS One 5:e9263.
32. Kawamura, N., et al. 1989. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1302-1309.
33. Kew, O. M., B. K. Nottay, M. H. Hatch, J. H. Nakano, and J. F. Obijeski. 1981. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J. Gen. Virol. 56:337-347.
34. Kirkegaard, K. 1990. Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA. J. Virol. 64:195-206.
35. Koike, S., et al. 1991. Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 88:951-955.
36. Lancaster, K. Z., and J. K. Pfeiffer. 2010. Limited trafficking of a neurotropic virus through inefficient retrograde axonal transport and the type I interferon response. PLoS Pathog. 6:e1000791.
37. Lataillade, M., et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 5:e10952.
38. Lauring, A. S., and R. Andino. 2010. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 6:e1001005.
39. Li, J., et al. 1996. Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients. Arch. Virol. 141:1047-1054.
40. Liu, L., et al. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J. Virol. 84:5067-5077.
41. Macadam, A. J., et al. 1993. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18-26.
42. Mandel, B. 1967. The relationship between penetration and uncoating of poliovirus in HeLa cells. Virology 31:702-712.
43. Martin, A., et al. 1991. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology 180:648-658.
44. Martinez, C. V., et al. 2004. Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J. Infect. Dis. 190:409-416.
45. Minor, P. D., A. John, M. Ferguson, and J. P. Icenogle. 1986. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J. Gen. Virol. 67(Pt. 4):693-706.
46. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
47. Ohka, S., et al. 2007. Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J. Virol. 81:7902-7912.
48. Ohka, S., et al. 2009. Receptor-dependent and -independent axonal retrograde transport of poliovirus in motor neurons. J. Virol. 83:4995-5004.
49. Ohka, S., W. X. Yang, E. Terada, K. Iwasaki, and A. Nomoto. 1998. Retrograde transport of intact poliovirus through the axon via the fast transport system. Virology 250:67-75.
50. Pallansch, M. A., and R. P. Roos. 2001. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p. 723-777. In D. M. Knipe et al. (ed.), Fields virology, 4th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
51. Paul, A. V., et al. 2000. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology 272:72-84.
52. Perales, C., R. Mateo, M. G. Mateu, and E. Domingo. 2007. Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J. Mol. Biol. 369:985-1000.
53. Pfeiffer, J. K., and K. Kirkegaard. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 100:7289-7294.
54. Pohjanpelto, P., and P. D. Cooper. 1965. Interference between polioviruses induced by strains that cannot multiply. Virology 25:350-357.
55. Ren, R., and V. R. Racaniello. 1992. Poliovirus spreads from muscle to the central nervous system by neural pathways. J. Infect. Dis. 166:747-752.
56. Ren, R. B., F. Costantini, E. J. Gorgacz, J. J. Lee, and V. R. Racaniello. 1990. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63:353-362.
57. Roberts, L. 2010. Infectious disease. Polio outbreak breaks the rules. Science 330:1730-1731.
58. Sabin, A., and L. Boulger. 1973. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1:115-118.
59. Sanz-Ramos, M., F. Diaz-San Segundo, C. Escarmis, E. Domingo, and N. Sevilla. 2008. Hidden virulence determinants in a viral quasispecies in vivo. J. Virol. 82:10465-10476.
60. Schneider, W. L., and M. J. Roossinck. 2001. Genetic diversity in RNA virus quasispecies is controlled by host-virus interactions. J. Virol. 75:6566-6571.
61. Stauffer Thompson, K. A., G. A. Rempala, and J. Yin. 2009. Multiple-hit inhibition of infection by defective interfering particles. J. Gen. Virol. 90: 888-899.
62. Steinhauer, D. A., and J. J. Holland. 1987. Rapid evolution of RNA viruses. Annu. Rev. Microbiol. 41:409-433.
63. Teng, M. N., M. B. Oldstone, and J. C. de la Torre. 1996. Suppression of lymphocytic choriomeningitis virus-induced growth hormone deficiency syndrome by disease-negative virus variants. Virology 223:113-119.
64. Whitaker-Dowling, P., and J. S. Youngner. 1987. Viral interference-dominance of mutant viruses over wild-type virus in mixed infections. Microbiol. Rev. 51:179-191.
65. Wolinsky, S. M., et al. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542.
66. Wringe, A., P. E. Fine, R. W. Sutter, and O. M. Kew. 2008. Estimating the extent of vaccine-derived poliovirus infection. PLoS One 3:e3433.
67. Yang, C. F., et al. 2005. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79:12623-12634.
68. Yoneyama, T., et al. 2001. Neurovirulence of Sabin 1-derived polioviruses isolated from an immunodeficient patient with prolonged viral excretion. Dev. Biol. (Basel) 105:93-98.